A number of other equities research analysts have also weighed in on DCTH. StockNews.com initiated coverage on shares of Delcath Systems in a report on Sunday. They set a “sell” rating on the stock. HC Wainwright decreased their target price on shares of Delcath Systems from $25.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, August 10th.
Delcath Systems Price Performance
Shares of DCTH opened at $2.80 on Tuesday. The firm has a market capitalization of $24.07 million, a PE ratio of -0.74 and a beta of 0.92. The company has a debt-to-equity ratio of 2.55, a current ratio of 1.28 and a quick ratio of 1.15. Delcath Systems has a 1-year low of $2.34 and a 1-year high of $10.24. The company’s fifty day moving average price is $3.18 and its 200-day moving average price is $3.93.
Institutional Inflows and Outflows
Delcath Systems Company Profile
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Get a free copy of the StockNews.com research report on Delcath Systems (DCTH)
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- International Game Technology is Well Worth the Gamble
- Use The Airbnb Stock Implosion to Your Advantage
- Why Lowe’s Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.